Immunochemotherapy for visceral leishmaniasis: a controlled pilot trial of antimony versus antimony plus interferon-gamma

Am J Trop Med Hyg. 1993 May;48(5):666-9. doi: 10.4269/ajtmh.1993.48.666.

Abstract

Twenty-four Kenyan patients with visceral leishmaniasis were treated for 30 days with either conventional therapy (daily pentavalent antimony, n = 14) or experimental immunochemotherapy (daily antimony plus interferon-gamma [IFN-gamma] every other day, n = 10). All 24 patients responded clinically to treatment, and microscopic splenic aspirate scores rapidly decreased in both groups. As judged by splenic aspirate culture results, IFN-gamma-treated patients responded more quickly (50% versus 22% culture-negative after one week and 75% versus 58% culture-negative after two weeks). While not statistically significant, these differences raise the possibility that combination therapy using IFN-gamma, which was safe and well-tolerated, may accelerate the early parasitologic response in patients with visceral leishmaniasis.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adolescent
  • Adult
  • Animals
  • Antimony Sodium Gluconate / therapeutic use*
  • Child
  • Child, Preschool
  • Drug Therapy, Combination
  • Drug Tolerance
  • Female
  • Follow-Up Studies
  • Humans
  • Interferon-gamma / adverse effects
  • Interferon-gamma / therapeutic use*
  • Leishmania donovani / isolation & purification
  • Leishmaniasis, Visceral / drug therapy*
  • Male
  • Pilot Projects
  • Prospective Studies
  • Recombinant Proteins
  • Spleen / parasitology

Substances

  • Recombinant Proteins
  • Interferon-gamma
  • Antimony Sodium Gluconate